Omeros Corporation

Healthcare · Biotechnology · United States

Last price 18.18 USD (Oct 30, 2026, 3:13 PM EDT) · Market cap 1.32B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-bind...